NP1867 / NeoPhore - LARVOL DELTA

A Cell-Based MSI Reporter Platform Identifies QHT025: A First-in-Class MMRd-Inducing Compound Sensitizing MMRp Tumors to Immunotherapy (SITC 2025) - "QHT025 showed superior potency in driving MSI-H and converting MMRp→MMRd versus reference compounds (NP1867, TMZ).Conclusions This platform establishes an innovative cell-based assay for assessing MSI activity...Acting as an immune-priming agent, it remodels the TME to convert 'cold' tumors to 'hot' lesions. The platform and compound pioneer a novel therapeutic approach to sensitize MMRp tumors to immunotherapy."

dMMR • IO biomarker • Tumor mutational burden • Colorectal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI • TMB

Pharmacological inhibition of PMS2 increases tumor mutational burden, induces microsatellite instability and elicits immune mediated rejection in vivo (AACR 2024) - "In conclusion, small molecule NP1867 functionally inhibits DNA MMR by targeting PMS2, enriches gained mutations with MMR-d COSMIC signatures, elicits MSI-H status, and enhances immune surveillance in preclinical models. These findings pave the way for the development of orally bioavailable compounds suitable for long-term dosing in animal models."

IO biomarker • Preclinical • Tumor mutational burden • Colorectal Cancer • Gastrointestinal Cancer • Microsatellite Instability • Oncology • Solid Tumor • MSI • PMS2 • TMB